Patents by Inventor Anders Krarup

Anders Krarup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins
    Patent number: 11896663
    Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: February 13, 2024
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Danielle Van Manen, Jort Vellinga, Frank Wegmann, Benoit Christophe Stephan Callendret, Anders Krarup, Jörn Stitz
  • STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES
    Publication number: 20230265127
    Abstract: Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.
    Type: Application
    Filed: August 23, 2022
    Publication date: August 24, 2023
    Inventors: Johannes Petrus Maria LANGEDIJK, Anders Krarup
  • STABILIZED SOLUBLE PRE-FUSION RSV F PROTEINS
    Publication number: 20220089652
    Abstract: Stable pre-fusion respiratory syncytial virus (RSV) F proteins (or fragment thereof) are described. Compositions containing the proteins and uses of the compositions for the prevention and/or treatment of RSV infection are also described.
    Type: Application
    Filed: October 8, 2021
    Publication date: March 24, 2022
    Inventors: Anders KRARUP, Johannes Petrus Maria LANGEDIJK
  • Stabilized soluble pre-fusion RSV F proteins
    Patent number: 11155583
    Abstract: Stable pre-fusion respiratory syncitial virus (RSV) F proteins (or fragment thereof) are described. Compositions containing the proteins and uses of the compositions for the prevention and/or treatment of RSV infection are also described.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: October 26, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Anders Krarup, Johannes Petrus Maria Langedijk
  • Compositions and Vaccine Combinations Containing Synthetic Human Immunodeficiency Virus (HIV) Envelope Antigen, and Methods of Use Thereof
    Publication number: 20210220468
    Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
    Type: Application
    Filed: March 3, 2021
    Publication date: July 22, 2021
    Inventors: Johannes Petrus Maria LANGEDIJK, Danielle VAN MANEN, Jort VELLINGA, Frank WEGMANN, Benoit Christophe Stephan CALLENDRET, Anders KRARUP, Jörn STITZ
  • Recombinant adenoviruses encoding mosaic human immunodeficiency virus (HIV) Env, Gag, and Pol antigens
    Patent number: 10973907
    Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Danielle Van Manen, Jort Vellinga, Frank Wegmann, Benoit Christophe Stephan Callendret, Anders Krarup, Jörn Stitz
  • Stabilized Soluble Pre-Fusion RSV F Polypeptides
    Publication number: 20210101940
    Abstract: Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 8, 2021
    Inventors: Johannes Petrus Maria Langedijk, Anders Krarup
  • Stabilized soluble pre-fusion RSV F polypeptides
    Patent number: 10899800
    Abstract: Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: January 26, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Anders Krarup
  • Compositions and Vaccine Combinations Containing Synthetic Human Immunodeficiency Virus (HIV) Envelope Antigen, and Methods of Use Thereof
    Publication number: 20190321462
    Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
    Type: Application
    Filed: June 13, 2019
    Publication date: October 24, 2019
    Applicant: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria LANGEDIJK, Danielle VAN MANEN, Jort VELLINGA, Frank WEGMANN, Benoit Christophe Stephan CALLENDRET, Anders KRARUP, Jörn STITZ
  • Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof
    Patent number: 10369214
    Abstract: Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 6, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Danielle Van Manen, Jort Vellinga, Frank Wegmann, Benoit Christophe Stephan Callendret, Anders Krarup, Jörn Stitz
  • Stabilized soluble pre-fusion RSV F polypeptides
    Patent number: 10294279
    Abstract: This disclosure provides stable pre-fusion respiratory syncytial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides, and uses thereof for the prevention and/or treatment of RSV infection.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: May 21, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes P. M. Langedijk, Anders Krarup
  • STABILIZED SOLUBLE PRE-FUSION RSV F PROTEINS
    Publication number: 20190119330
    Abstract: Stable pre-fusion respiratory syncitial virus (RSV) F proteins (or fragment thereof) are described. Compositions containing the proteins and uses of the compositions for the prevention and/or treatment of RSV infection are also described.
    Type: Application
    Filed: April 4, 2017
    Publication date: April 25, 2019
    Inventors: Anders KRARUP, Johannes Petrus Maria LANGEDIJK
  • STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES
    Publication number: 20160176932
    Abstract: This disclosure provides stable pre-fusion respiratory syncytial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides, and uses thereof for the prevention and/or treatment of RSV infection.
    Type: Application
    Filed: June 17, 2014
    Publication date: June 23, 2016
    Inventors: Johannes P.M. Langedijk, Anders Krarup
  • STABILIZED SOLUBLE PREFUSION RSV F POLYPEPTIDES
    Publication number: 20160102123
    Abstract: Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection.
    Type: Application
    Filed: April 24, 2014
    Publication date: April 14, 2016
    Inventors: Johannes Petrus Maria Langedijk, Anders Krarup